NASDAQ:GHDX - Genomic Health Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$38.52 +0.14 (+0.36 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$38.52
Today's Range$36.9383 - $38.68
52-Week Range$26.54 - $39.17
Volume171,827 shs
Average Volume179,234 shs
Market Capitalization$1.36 billion
P/E Ratio3,852.00
Dividend YieldN/A
Beta0.62

About Genomic Health (NASDAQ:GHDX)

Genomic Health logoGenomic Health, Inc., a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. The company offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the breast cancer recurrence and chemotherapy benefit. It also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy. In addition, the company provides the Oncotype DX tests for patients with ductal carcinoma in situ, a pre-invasive form of breast cancer; the Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk disease, as well as used to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score or tumor grading; and Oncotype DX AR-V7 Nucleus Detect test for men with metastatic castration-resistant prostate cancer. The company offers its products through a network of distributors. Genomic Health, Inc. has collaboration agreement with Epic Sciences, Inc.; license and development agreement with Biocartis N.V.; license agreement with Cleveland Diagnostics, Inc.; and a research collaboration agreement with Janssen Pharmaceuticals. The company was founded in 2000 and is based in Redwood City, California.

Receive GHDX News and Ratings via Email

Sign-up to receive the latest news and ratings for GHDX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:GHDX
CUSIP37244C10
Phone650-556-9300

Debt

Debt-to-Equity RatioN/A
Current Ratio4.94
Quick Ratio4.94

Price-To-Earnings

Trailing P/E Ratio3,852.00
Forward P/E Ratio85.60
P/E GrowthN/A

Sales & Book Value

Annual Sales$340.75 million
Price / Sales4.00
Cash Flow$0.3491 per share
Price / Cash110.34
Book Value$5.66 per share
Price / Book6.81

Profitability

EPS (Most Recent Fiscal Year)$0.01
Net Income$-3,850,000.00
Net Margins-1.95%
Return on Equity3.15%
Return on Assets2.54%

Miscellaneous

Employees863
Outstanding Shares35,380,000

Genomic Health (NASDAQ:GHDX) Frequently Asked Questions

What is Genomic Health's stock symbol?

Genomic Health trades on the NASDAQ under the ticker symbol "GHDX."

How were Genomic Health's earnings last quarter?

Genomic Health (NASDAQ:GHDX) issued its quarterly earnings data on Wednesday, May, 2nd. The medical research company reported $0.13 EPS for the quarter, beating the consensus estimate of $0.05 by $0.08. The medical research company earned $92.60 million during the quarter, compared to the consensus estimate of $88.95 million. Genomic Health had a negative net margin of 1.95% and a positive return on equity of 3.15%. The company's quarterly revenue was up 12.5% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.02) earnings per share. View Genomic Health's Earnings History.

When is Genomic Health's next earnings date?

Genomic Health is scheduled to release their next quarterly earnings announcement on Monday, July, 30th 2018. View Earnings Estimates for Genomic Health.

What guidance has Genomic Health issued on next quarter's earnings?

Genomic Health updated its FY18 earnings guidance on Thursday, March, 8th. The company provided earnings per share guidance of $0.32-0.50 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.35. The company issued revenue guidance of $366-382 million, compared to the consensus revenue estimate of $383.16 million.

What price target have analysts set for GHDX?

8 brokerages have issued 12-month price targets for Genomic Health's shares. Their forecasts range from $25.00 to $42.00. On average, they anticipate Genomic Health's stock price to reach $32.8571 in the next twelve months. View Analyst Ratings for Genomic Health.

Who are some of Genomic Health's key competitors?

Who are Genomic Health's key executives?

Genomic Health's management team includes the folowing people:
  • Ms. Kimberly J. Popovits, Chairman, CEO & Pres (Age 59)
  • Dr. Steven Shak, Co-Founder, Chief Scientific Officer & Chief Medical Officer (Age 67)
  • Mr. G. Bradley Cole, Chief Financial Officer (Age 62)
  • Dr. Frederic G. Pla, Chief Operating Officer (Age 59)
  • Mr. James J. Vaughn, Chief Commercial Officer (Age 55)

Has Genomic Health been receiving favorable news coverage?

Media headlines about GHDX stock have trended somewhat positive on Saturday, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Genomic Health earned a coverage optimism score of 0.17 on Accern's scale. They also assigned headlines about the medical research company an impact score of 46.36 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

Who are Genomic Health's major shareholders?

Genomic Health's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.47%), Loomis Sayles & Co. L P (1.38%), Schwab Charles Investment Management Inc. (1.22%), Point72 Asset Management L.P. (1.10%), Eagle Asset Management Inc. (0.85%) and Northern Trust Corp (0.76%). Company insiders that own Genomic Health stock include Felix Baker, Fred E Cohen, G Bradley Cole, James J Vaughn, Kimberly J Popovits, Laura Leber, Phillip G Febbo and Steven Shak. View Institutional Ownership Trends for Genomic Health.

Which institutional investors are selling Genomic Health stock?

GHDX stock was sold by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Wells Fargo & Company MN, Schwab Charles Investment Management Inc., UBS Group AG, Candriam Luxembourg S.C.A., BlackRock Inc., Loomis Sayles & Co. L P and University of Notre Dame DU Lac. Company insiders that have sold Genomic Health company stock in the last year include G Bradley Cole, James J Vaughn, Kimberly J Popovits, Laura Leber, Phillip G Febbo and Steven Shak. View Insider Buying and Selling for Genomic Health.

Which institutional investors are buying Genomic Health stock?

GHDX stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Carillon Tower Advisers Inc., Russell Investments Group Ltd., A.R.T. Advisors LLC, Algert Global LLC, Citadel Advisors LLC, GSA Capital Partners LLP and Alambic Investment Management L.P.. View Insider Buying and Selling for Genomic Health.

How do I buy shares of Genomic Health?

Shares of GHDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Genomic Health's stock price today?

One share of GHDX stock can currently be purchased for approximately $38.52.

How big of a company is Genomic Health?

Genomic Health has a market capitalization of $1.36 billion and generates $340.75 million in revenue each year. The medical research company earns $-3,850,000.00 in net income (profit) each year or $0.01 on an earnings per share basis. Genomic Health employs 863 workers across the globe.

How can I contact Genomic Health?

Genomic Health's mailing address is 301 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The medical research company can be reached via phone at 650-556-9300 or via email at [email protected]


MarketBeat Community Rating for Genomic Health (GHDX)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  195 (Vote Outperform)
Underperform Votes:  292 (Vote Underperform)
Total Votes:  487
MarketBeat's community ratings are surveys of what our community members think about Genomic Health and other stocks. Vote "Outperform" if you believe GHDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GHDX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Genomic Health (NASDAQ:GHDX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
8 Wall Street analysts have issued ratings and price targets for Genomic Health in the last 12 months. Their average twelve-month price target is $32.8571, suggesting that the stock has a possible downside of 14.70%. The high price target for GHDX is $42.00 and the low price target for GHDX is $25.00. There are currently 2 sell ratings, 5 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 1.881.881.882.00
Ratings Breakdown: 2 Sell Rating(s)
5 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
5 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
5 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
5 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $32.8571$32.6667$32.3333$32.6667
Price Target Upside: 14.70% downside3.67% upside8.66% downside15.10% upside

Genomic Health (NASDAQ:GHDX) Consensus Price Target History

Price Target History for Genomic Health (NASDAQ:GHDX)

Genomic Health (NASDAQ:GHDX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/3/2018Deutsche BankBoost Price TargetHold ➝ Hold$32.00 ➝ $34.00MediumView Rating Details
3/8/2018Piper Jaffray CompaniesReiterated RatingHold$33.00HighView Rating Details
1/16/2018Canaccord GenuityReiterated RatingBuy$42.00LowView Rating Details
1/8/2018BarclaysReiterated RatingSell$28.00MediumView Rating Details
12/20/2017William BlairDowngradeOutperform ➝ Market PerformLowView Rating Details
12/13/2017JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$25.00HighView Rating Details
10/20/2017Jefferies GroupReiterated RatingHold$34.00N/AView Rating Details
9/1/2017CowenReiterated RatingHold$34.00LowView Rating Details
5/3/2017Raymond JamesReiterated RatingOutperform ➝ Market PerformHighView Rating Details
8/3/2016Bank of AmericaSet Price TargetSell$28.00N/AView Rating Details
6/21/2016Leerink SwannReiterated RatingBuyN/AView Rating Details
(Data available from 5/26/2016 forward)

Earnings

Genomic Health (NASDAQ:GHDX) Earnings History and Estimates Chart

Earnings by Quarter for Genomic Health (NASDAQ:GHDX)

Genomic Health (NASDAQ:GHDX) Earnings Estimates

2018 EPS Consensus Estimate: $0.34
2019 EPS Consensus Estimate: $0.69
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$0.01$0.07$0.04
Q2 20183$0.02$0.06$0.05
Q3 20183$0.11$0.13$0.12
Q4 20183$0.12$0.16$0.14
Q1 20192$0.16$0.19$0.18
Q2 20192$0.18$0.18$0.18
Q3 20192$0.12$0.19$0.16
Q4 20192$0.15$0.20$0.18

Genomic Health (NASDAQ GHDX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/30/2018$0.06N/AView Earnings Details
5/2/2018Q1 2018$0.05$0.13$88.95 million$92.60 millionViewListenView Earnings Details
3/8/2018Q4 2017$0.09$0.08$88.96 million$87.50 millionViewN/AView Earnings Details
11/8/2017Q3 2017($0.01)$0.03$87.06 million$83.82 millionViewN/AView Earnings Details
8/1/2017Q2 2017($0.06)($0.08)$86.08 million$85.50 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.06)($0.07)$86.21 million$84.00 millionViewListenView Earnings Details
2/14/2017Q416($0.01)$0.04$84.08 million$82.70 millionViewListenView Earnings Details
11/1/2016Q316($0.09)($0.08)$83.24 million$82.30 millionViewN/AView Earnings Details
8/2/2016Q216($0.18)($0.18)$81.27 million$81.97 millionViewN/AView Earnings Details
5/4/2016Q1($0.24)($0.19)$78.12 million$80.89 millionViewN/AView Earnings Details
2/10/2016Q415($0.09)($0.10)$74.03 million$74.50 millionViewListenView Earnings Details
11/3/2015Q315($0.18)($0.36)$73.35 million$73.60 millionViewN/AView Earnings Details
8/4/2015Q215($0.27)($0.29)$71.65 million$70.60 millionViewListenView Earnings Details
5/5/2015Q115($0.28)($0.30)$69.30 million$68.15 millionViewN/AView Earnings Details
2/10/2015Q414($0.21)($0.20)$72.20 million$69.10 millionViewN/AView Earnings Details
11/4/2014Q314($0.22)($0.20)$71.00 million$69.10 millionViewN/AView Earnings Details
8/7/2014Q214($0.28)($0.15)$69.04 million$70.50 millionViewN/AView Earnings Details
5/6/2014Q114($0.18)($0.24)$68.47 million$67.00 millionViewN/AView Earnings Details
2/4/2014Q413($0.03)($0.30)$69.20 million$68.80 millionViewN/AView Earnings Details
11/5/2013Q313($0.04)$0.02$64.98 million$65.99 millionViewN/AView Earnings Details
7/31/2013Q2 2013($0.08)($0.10)$63.91 million$63.70 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.02)($0.03)$62.90 million$63.10 millionViewN/AView Earnings Details
2/6/2013Q4 2012$0.03$0.06$58.90 million$60.40 millionViewN/AView Earnings Details
11/7/2012Q312$0.05$0.11$59.87 million$58.60 millionViewN/AView Earnings Details
8/8/2012($0.02)$0.06ViewN/AView Earnings Details
5/2/2012($0.02)$0.02ViewN/AView Earnings Details
2/6/2012$0.09$0.08ViewN/AView Earnings Details
11/1/2011$0.03$0.10ViewN/AView Earnings Details
8/3/2011$0.02$0.08ViewN/AView Earnings Details
5/3/2011$0.02($0.01)ViewN/AView Earnings Details
2/8/2011$0.06$0.06ViewN/AView Earnings Details
11/8/2010Q3 2010$0.12ViewN/AView Earnings Details
8/4/2010Q2 2010($0.02)$0.03ViewN/AView Earnings Details
5/5/2010Q1 2010($0.03)($0.07)ViewN/AView Earnings Details
2/3/2010Q4 2009($0.06)($0.01)ViewN/AView Earnings Details
11/4/2009Q3 2009($0.09)($0.02)ViewN/AView Earnings Details
8/4/2009Q2 2009($0.12)($0.14)ViewN/AView Earnings Details
5/5/2009Q1 2009($0.15)($0.16)ViewN/AView Earnings Details
2/3/2009Q4 2008($0.11)($0.08)ViewN/AView Earnings Details
11/5/2008Q3 2008($0.14)($0.11)ViewN/AView Earnings Details
8/5/2008Q2 2008($0.17)($0.15)ViewN/AView Earnings Details
5/6/2008Q1 2008($0.21)($0.24)ViewN/AView Earnings Details
2/5/2008Q4 2007($0.24)($0.21)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Genomic Health (NASDAQ:GHDX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Genomic Health (NASDAQ GHDX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 45.80%
Institutional Ownership Percentage: 89.89%
Insider Trading History for Genomic Health (NASDAQ:GHDX)
Institutional Ownership by Quarter for Genomic Health (NASDAQ:GHDX)

Genomic Health (NASDAQ GHDX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/14/2018Kimberly J. PopovitsCEOSell10,000$38.09$380,900.00View SEC Filing  
5/9/2018Steven ShakInsiderSell5,500$36.64$201,520.00View SEC Filing  
5/2/2018James J. VaughnInsiderSell1,497$32.50$48,652.50View SEC Filing  
4/16/2018Kimberly J. PopovitsInsiderSell15,000$33.19$497,850.00View SEC Filing  
3/13/2018G Bradley ColeCOOSell5,000$32.80$164,000.00View SEC Filing  
2/20/2018G Bradley ColeCOOSell5,000$32.89$164,450.00View SEC Filing  
2/20/2018Phillip G FebboInsiderSell4,942$32.84$162,295.28View SEC Filing  
2/14/2018Kimberly J PopovitsInsiderSell10,000$32.93$329,300.00View SEC Filing  
1/16/2018Kimberly J. PopovitsInsiderSell10,000$34.99$349,900.00View SEC Filing  
1/9/2018G Bradley ColeCOOSell5,000$35.51$177,550.00View SEC Filing  
1/2/2018James J. VaughnInsiderSell3,004$34.09$102,406.36View SEC Filing  
12/19/2017Phillip G. FebboInsiderSell5,334$36.99$197,304.66View SEC Filing  
12/15/2017Laura LeberInsiderSell21,000$33.29$699,090.00View SEC Filing  
12/14/2017Kimberly J. PopovitsCEOSell20,000$31.50$630,000.00View SEC Filing  
12/12/2017G Bradley ColeCOOSell5,000$29.94$149,700.00View SEC Filing  
11/7/2017G Bradley ColeCOOSell5,000$31.47$157,350.00View SEC Filing  
11/2/2017James J. VaughnInsiderSell1,379$32.51$44,831.29View SEC Filing  
10/10/2017G Bradley ColeCOOSell5,000$31.93$159,650.00View SEC Filing  
9/14/2017Kimberly J. PopovitsInsiderSell5,000$31.00$155,000.00View SEC Filing  
9/12/2017G Bradley ColeCOOSell5,000$31.86$159,300.00View SEC Filing  
8/14/2017Kimberly J. PopovitsInsiderSell5,000$30.22$151,100.00View SEC Filing  
8/8/2017G Bradley ColeCOOSell5,000$30.57$152,850.00View SEC Filing  
8/8/2017James J. VaughnInsiderSell8,000$30.59$244,720.00View SEC Filing  
7/19/2017Phillip G. FebboInsiderSell3,174$33.57$106,551.18View SEC Filing  
7/11/2017G Bradley ColeCOOSell5,000$32.53$162,650.00View SEC Filing  
7/5/2017Kimberly J. PopovitsInsiderSell5,000$32.59$162,950.00View SEC Filing  
7/5/2017Kimberly J. PopovitsCEOSell1,468$32.67$47,959.56View SEC Filing  
6/23/2017Steven ShakInsiderSell5,000$33.27$166,350.00View SEC Filing  
6/5/2017Kimberly J. PopovitsInsiderSell5,000$32.32$161,600.00View SEC Filing  
5/23/2017Steven ShakInsiderSell5,000$29.40$147,000.00View SEC Filing  
5/19/2017Fred E CohenDirectorSell8,250$29.54$243,705.0074,145View SEC Filing  
5/18/2017Fred E CohenDirectorSell16,500$29.88$493,020.0074,145View SEC Filing  
5/16/2017Fred E CohenDirectorSell8,250$30.68$253,110.0074,145View SEC Filing  
5/3/2017Kimberly J. PopovitsInsiderSell5,000$31.77$158,850.00View SEC Filing  
4/24/2017Steven ShakInsiderSell5,000$31.46$157,300.00View SEC Filing  
4/3/2017Kimberly J. PopovitsInsiderSell5,000$31.30$156,500.00View SEC Filing  
3/23/2017Steven ShakInsiderSell5,000$31.26$156,300.00View SEC Filing  
3/20/2017Laura LeberInsiderSell3,072$31.88$97,935.36View SEC Filing  
3/6/2017Kimberly J. PopovitsInsiderSell5,000$31.09$155,450.00View SEC Filing  
2/16/2017Phillip G. FebboInsiderSell2,495$30.09$75,074.55View SEC Filing  
1/23/2017Steven ShakInsiderSell5,000$27.28$136,400.00332,207View SEC Filing  
1/10/2017G Bradley ColeCOOSell5,000$29.22$146,100.0040,882View SEC Filing  
12/5/2016Kimberly J PopovitsInsiderSell5,000$30.02$150,100.0064,620View SEC Filing  
11/3/2016Kimberly J PopovitsInsiderSell5,313$28.88$153,439.4464,933View SEC Filing  
10/11/2016Steven ShakInsiderSell5,000$30.39$151,950.00332,207View SEC Filing  
10/10/2016G Bradley ColeCOOSell8,290$30.59$253,591.1039,426View SEC Filing  
10/6/2016James J. VaughnInsiderSell3,000$29.68$89,040.00View SEC Filing  
9/13/2016Steven ShakInsiderSell5,000$26.83$134,150.00332,207View SEC Filing  
8/23/2016Steven ShakInsiderSell5,000$27.24$136,200.00332,207View SEC Filing  
8/15/2016Felix BakerDirectorBuy100,000$27.02$2,702,000.00View SEC Filing  
8/11/2016G Bradley ColeCOOSell5,000$28.87$144,350.0040,426View SEC Filing  
8/8/2016James J. VaughnInsiderSell3,000$28.74$86,220.00View SEC Filing  
7/19/2016Steven ShakInsiderSell5,000$27.42$137,100.00332,207View SEC Filing  
7/6/2016G Bradley ColeCOOSell5,000$26.64$133,200.0040,426View SEC Filing  
6/21/2016Steven ShakInsiderSell5,000$25.77$128,850.00332,107View SEC Filing  
6/9/2016G Bradley ColeCOOSell5,000$26.62$133,100.0040,226View SEC Filing  
6/6/2016James J VaughnInsiderSell1,997$28.00$55,916.0034,076View SEC Filing  
5/16/2016G Bradley ColeCOOSell5,000$27.60$138,000.0039,970View SEC Filing  
5/10/2016Phillip G FebboInsiderSell6,324$27.20$172,012.8015,113View SEC Filing  
5/4/2016Steven ShakInsiderSell10,000$25.43$254,300.00336,383View SEC Filing  
1/13/2016Randall S. LivingstonDirectorSell1,250$32.14$40,175.006,149View SEC Filing  
1/12/2016G Bradley ColeCOOSell4,000$31.69$126,760.0027,428View SEC Filing  
1/7/2016James J. VaughninsiderSell2,000$33.63$67,260.0024,076View SEC Filing  
12/8/2015G Bradley ColeCOOSell4,000$29.26$117,040.0027,428View SEC Filing  
12/7/2015James J. VaughninsiderSell2,000$29.33$58,660.0024,076View SEC Filing  
11/10/2015G Bradley ColeCOOSell4,000$26.03$104,120.0030,326View SEC Filing  
9/9/2015G Bradley ColeCOOSell9,664$25.35$244,982.4030,326View SEC Filing  
7/7/2015G Bradley ColeCOOSell4,000$27.53$110,120.00View SEC Filing  
6/9/2015G Bradley ColeCOOSell4,000$26.24$104,960.00View SEC Filing  
4/13/2015Kimberly J PopovitsCEOSell3,000$31.28$93,840.00View SEC Filing  
4/7/2015G Bradley ColeCOOSell4,000$30.44$121,760.00View SEC Filing  
2/2/2015Randall S LivingstonDirectorSell1,000$31.93$31,930.00View SEC Filing  
1/12/2015Kimberly J PopovitsCEOSell3,000$33.46$100,380.00View SEC Filing  
12/8/2014G Bradley ColeCOOSell4,336$32.52$141,006.72View SEC Filing  
11/12/2014Kimberly J PopovitsCEOSell4,300$34.82$149,726.00View SEC Filing  
10/13/2014Kimberly J PopovitsCEOSell3,000$30.78$92,340.00View SEC Filing  
10/8/2014G Bradley ColeCOOSell4,000$28.77$115,080.00View SEC Filing  
9/11/2014Kimberly J PopovitsCEOSell3,000$29.82$89,460.00View SEC Filing  
9/8/2014G Bradley ColeCOOSell4,700$30.09$141,423.00View SEC Filing  
8/14/2014Steven ShakEVPSell13,348$27.36$365,201.28View SEC Filing  
8/13/2014Steven ShakEVPSell7,000$27.25$190,750.00View SEC Filing  
7/14/2014Kimberly J PopovitsCEOSell3,000$26.59$79,770.00View SEC Filing  
7/8/2014G Bradley ColeCOOSell2,300$27.05$62,215.00View SEC Filing  
7/1/2014Steven ShakEVPSell7,000$27.00$189,000.00View SEC Filing  
4/14/2014Steven ShakEVPSell7,000$26.25$183,750.00311,588View SEC Filing  
4/8/2014G Bradley ColeCOOSell3,000$27.00$81,000.0022,226View SEC Filing  
3/14/2014Steven ShakEVPSell7,000$28.36$198,520.00311,588View SEC Filing  
2/18/2014Kathy HibbsSVPSell1,312$27.88$36,578.5615,787View SEC Filing  
1/15/2014Steven ShakEVPSell7,000$31.51$220,570.00308,283View SEC Filing  
1/13/2014Kimberly PopovitsCEOSell2,500$30.00$75,000.0026,866View SEC Filing  
12/17/2013Steven ShakCMOSell14,000$29.57$413,980.00308,283View SEC Filing  
12/12/2013Kimberly PopovitsCEOSell2,500$30.68$76,700.0026,866View SEC Filing  
12/9/2013Dean SchornoCFOSell3,000$33.25$99,750.0021,557View SEC Filing  
10/15/2013Steven ShakCMOSell5,000$29.67$148,350.00View SEC Filing  
10/10/2013Kimberly PopovitsCEOSell2,500$30.00$75,000.0026,866View SEC Filing  
10/9/2013G Bradley ColeCOOSell2,500$29.95$74,875.0018,135View SEC Filing  
9/18/2013Steven ShakCMOSell5,000$33.73$168,650.00313,283View SEC Filing  
9/12/2013Kimberly PopovitsCEOSell2,500$34.31$85,775.0026,866View SEC Filing  
9/9/2013G Bradley ColeCOOSell2,500$32.53$81,325.00View SEC Filing  
9/6/2013Dean L SchornoCFOSell4,000$32.90$131,600.00View SEC Filing  
9/3/2013Randall LivingstonDirectorSell1,000$31.49$31,490.006,149View SEC Filing  
8/14/2013Steven ShakCMOSell5,000$32.98$164,900.00318,283View SEC Filing  
8/12/2013Kimberly PopovitsCEOSell2,500$33.03$82,575.0026,866View SEC Filing  
8/9/2013Dean SchornoCFOSell4,000$33.15$132,600.0021,436View SEC Filing  
8/7/2013G Bradley ColeCOOSell2,500$33.66$84,150.0019,135View SEC Filing  
7/23/2013Steven ShakCMOSell5,000$35.33$176,650.00View SEC Filing  
7/12/2013Kimberly J PopovitsCEOSell5,000$34.61$173,050.00View SEC Filing  
7/9/2013Dean L SchornoCFOSell4,000$33.81$135,240.00View SEC Filing  
7/8/2013G Bradley ColeCOOSell2,500$33.33$83,325.00View SEC Filing  
6/18/2013Steven ShakCMOSell5,000$33.52$167,600.00View SEC Filing  
6/12/2013Kimberly J PopovitsCEOSell5,000$35.68$178,400.00View SEC Filing  
6/10/2013Dean L SchornoCFOSell4,000$35.88$143,520.00View SEC Filing  
6/5/2013Felix BakerDirectorBuy381,432$36.16$13,792,581.12View SEC Filing  
6/5/2013G Bradley ColeCOOSell2,500$36.47$91,175.00View SEC Filing  
6/3/2013Felix BakerDirectorBuy179,583$36.71$6,592,491.93View SEC Filing  
5/29/2013Felix BakerDirectorBuy121,266$36.89$4,473,502.74View SEC Filing  
5/24/2013Felix BakerDirectorBuy79,417$36.93$2,932,869.81View SEC Filing  
5/22/2013Kathy L HibbsSVPSell1,000$37.48$37,480.00View SEC Filing  
5/21/2013Steven ShakCMOSell5,000$37.19$185,950.00View SEC Filing  
5/16/2013Felix BakerDirectorBuy71,439$36.45$2,603,951.55View SEC Filing  
5/15/2013Randall S LivingstonDirectorSell1,337$35.83$47,904.71View SEC Filing  
5/14/2013Felix BakerDirectorBuy240,426$34.34$8,256,228.84View SEC Filing  
5/13/2013Kathy L HibbsSVPSell1,250$34.42$43,025.00View SEC Filing  
5/13/2013Kimberly J PopovitsCEOSell5,000$34.70$173,500.00View SEC Filing  
5/9/2013Dean L SchornoCFOSell4,000$36.02$144,080.00View SEC Filing  
5/8/2013G Bradley ColeCOOSell2,500$35.99$89,975.00View SEC Filing  
2/21/2013Felix BakerDirectorBuy49,085$27.78$1,363,581.30View SEC Filing  
2/14/2013Woodrow A Myers JrDirectorSell41,250$28.40$1,171,500.00View SEC Filing  
2/11/2013Felix BakerDirectorBuy116,360$28.15$3,275,534.00View SEC Filing  
11/26/2012Randall S LivingstonDirectorSell2,000$27.84$55,680.00View SEC Filing  
11/21/2012Felix BakerDirectorBuy229,300$26.83$6,152,119.00View SEC Filing  
11/14/2012Felix BakerDirectorBuy103,167$27.32$2,818,522.44View SEC Filing  
11/13/2012Felix BakerDirectorBuy823,772$27.81$22,909,099.32View SEC Filing  
11/12/2012Dean L SchornoCFOSell3,000$28.00$84,000.00View SEC Filing  
11/8/2012G Bradley ColeCOOSell2,500$28.62$71,550.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Genomic Health (NASDAQ GHDX) News Headlines

Source:
DateHeadline
Genomic Health (GHDX) versus Cancer Genetics (CGIX) Head to Head ReviewGenomic Health (GHDX) versus Cancer Genetics (CGIX) Head to Head Review
www.americanbankingnews.com - May 25 at 3:25 PM
Comparing Genomic Health (GHDX) & Miragen Therapeutics (MGEN)Comparing Genomic Health (GHDX) & Miragen Therapeutics (MGEN)
www.americanbankingnews.com - May 22 at 3:10 AM
New data reinforce positive impact of the Oncotype DX GPS test in guiding treatment decisionsNew data reinforce positive impact of the Oncotype DX GPS test in guiding treatment decisions
seekingalpha.com - May 21 at 9:16 AM
Contrasting Genomic Health (GHDX) and Quest Diagnostics (DGX)Contrasting Genomic Health (GHDX) and Quest Diagnostics (DGX)
www.americanbankingnews.com - May 19 at 11:21 AM
Financial Review: Genomic Health (GHDX) and Cancer Genetics (CGIX)Financial Review: Genomic Health (GHDX) and Cancer Genetics (CGIX)
www.americanbankingnews.com - May 18 at 11:57 AM
Here's Why You Should Sell DENTSPLY SIRONA (XRAY) Stock NowHere's Why You Should Sell DENTSPLY SIRONA (XRAY) Stock Now
finance.yahoo.com - May 18 at 10:22 AM
Genomic Health (GHDX) Expected to Post Quarterly Sales of $91.22 MillionGenomic Health (GHDX) Expected to Post Quarterly Sales of $91.22 Million
www.americanbankingnews.com - May 18 at 2:52 AM
Insider Selling: Genomic Health (GHDX) CEO Sells 10,000 Shares of StockInsider Selling: Genomic Health (GHDX) CEO Sells 10,000 Shares of Stock
www.americanbankingnews.com - May 16 at 7:50 PM
Can The Uptrend Continue for Genomic Health (GHDX)?Can The Uptrend Continue for Genomic Health (GHDX)?
finance.yahoo.com - May 16 at 4:29 PM
Zacks: Analysts Anticipate Genomic Health (GHDX) to Post $0.07 EPSZacks: Analysts Anticipate Genomic Health (GHDX) to Post $0.07 EPS
www.americanbankingnews.com - May 16 at 3:39 PM
Genomic Health (GHDX) Rating Increased to Strong-Buy at BidaskClubGenomic Health (GHDX) Rating Increased to Strong-Buy at BidaskClub
www.americanbankingnews.com - May 12 at 4:24 PM
Genomic Health (GHDX) Stock Rating Upgraded by ValuEngineGenomic Health (GHDX) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - May 11 at 9:23 PM
Genomic Health (GHDX) Insider Steven Shak Sells 5,500 SharesGenomic Health (GHDX) Insider Steven Shak Sells 5,500 Shares
www.americanbankingnews.com - May 11 at 4:41 PM
Here's Why You Should Invest in Varian Medical (VAR) NowHere's Why You Should Invest in Varian Medical (VAR) Now
finance.yahoo.com - May 11 at 10:24 AM
Genomic Health (GHDX) Raised to Strong-Buy at Zacks Investment ResearchGenomic Health (GHDX) Raised to Strong-Buy at Zacks Investment Research
www.americanbankingnews.com - May 9 at 5:11 PM
Genomic Health to Present at Bank of America Merrill Lynch 2018 Health Care ConferenceGenomic Health to Present at Bank of America Merrill Lynch 2018 Health Care Conference
finance.yahoo.com - May 9 at 9:31 AM
Analysts Offer Predictions for Genomic Healths Q3 2018 Earnings (GHDX)Analysts Offer Predictions for Genomic Health's Q3 2018 Earnings (GHDX)
www.americanbankingnews.com - May 7 at 3:23 AM
Genomic Health (GHDX) to Post Q2 2018 Earnings of $0.06 Per Share, Piper Jaffray ForecastsGenomic Health (GHDX) to Post Q2 2018 Earnings of $0.06 Per Share, Piper Jaffray Forecasts
www.americanbankingnews.com - May 7 at 2:11 AM
James J. Vaughn Sells 1,497 Shares of Genomic Health (GHDX) StockJames J. Vaughn Sells 1,497 Shares of Genomic Health (GHDX) Stock
www.americanbankingnews.com - May 4 at 10:15 PM
Genomic Health Starts the Year off RightGenomic Health Starts the Year off Right
www.fool.com - May 4 at 3:13 PM
Genomic Health (GHDX) Expected to Post Q2 2018 Earnings of $0.06 Per ShareGenomic Health (GHDX) Expected to Post Q2 2018 Earnings of $0.06 Per Share
www.americanbankingnews.com - May 4 at 7:57 AM
Genomic Health (GHDX) Lifted to Hold at ValuEngineGenomic Health (GHDX) Lifted to Hold at ValuEngine
www.americanbankingnews.com - May 4 at 12:00 AM
Genomic Health (GHDX) Price Target Raised to $34.00Genomic Health (GHDX) Price Target Raised to $34.00
www.americanbankingnews.com - May 3 at 11:03 PM
Genomic Health (GHDX) Releases Quarterly  Earnings Results, Beats Estimates By $0.08 EPSGenomic Health (GHDX) Releases Quarterly Earnings Results, Beats Estimates By $0.08 EPS
www.americanbankingnews.com - May 3 at 7:29 PM
Head to Head Analysis: Natera (NTRA) & Genomic Health (GHDX)Head to Head Analysis: Natera (NTRA) & Genomic Health (GHDX)
www.americanbankingnews.com - May 3 at 3:24 PM
Genomic Healths (GHDX) CEO Kimberly Popovits on Q1 2018 Results - Earnings Call TranscriptGenomic Health's (GHDX) CEO Kimberly Popovits on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 3 at 9:21 AM
Edited Transcript of GHDX earnings conference call or presentation 2-May-18 8:30pm GMTEdited Transcript of GHDX earnings conference call or presentation 2-May-18 8:30pm GMT
finance.yahoo.com - May 3 at 9:21 AM
Genomic Health: 1Q Earnings SnapshotGenomic Health: 1Q Earnings Snapshot
finance.yahoo.com - May 3 at 9:21 AM
Genomic Health (GHDX) Given Average Recommendation of "Hold" by AnalystsGenomic Health (GHDX) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - May 3 at 3:24 AM
Genomic Health Announces First Quarter 2018 Financial Results and Reports Recent Business ProgressGenomic Health Announces First Quarter 2018 Financial Results and Reports Recent Business Progress
finance.yahoo.com - May 2 at 4:30 PM
$88.67 Million in Sales Expected for Genomic Health (GHDX) This Quarter$88.67 Million in Sales Expected for Genomic Health (GHDX) This Quarter
www.americanbankingnews.com - May 1 at 4:43 AM
Notable Two Hundred Day Moving Average Cross - GHDXNotable Two Hundred Day Moving Average Cross - GHDX
www.nasdaq.com - April 30 at 4:26 PM
Genomic Health (GHDX) Set to Announce Earnings on MondayGenomic Health (GHDX) Set to Announce Earnings on Monday
www.americanbankingnews.com - April 30 at 9:21 AM
 Brokerages Expect Genomic Health (GHDX) Will Post Earnings of $0.02 Per Share Brokerages Expect Genomic Health (GHDX) Will Post Earnings of $0.02 Per Share
www.americanbankingnews.com - April 29 at 1:16 AM
Large Independent Study Using the Oncotype DX® Test Accepted for Presentation at 2018 American Society of Clinical Oncology (ASCO) Annual MeetingLarge Independent Study Using the Oncotype DX® Test Accepted for Presentation at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
finance.yahoo.com - April 26 at 9:16 AM
Genomic Health to Announce First Quarter 2018 Financial Results and Host Conference Call on Wednesday, May 2, 2018Genomic Health to Announce First Quarter 2018 Financial Results and Host Conference Call on Wednesday, May 2, 2018
finance.yahoo.com - April 25 at 9:34 AM
Genomic Health (GHDX) Downgraded by ValuEngineGenomic Health (GHDX) Downgraded by ValuEngine
www.americanbankingnews.com - April 20 at 12:24 AM
Kimberly J. Popovits Sells 15,000 Shares of Genomic Health (GHDX) StockKimberly J. Popovits Sells 15,000 Shares of Genomic Health (GHDX) Stock
www.americanbankingnews.com - April 18 at 7:29 PM
Genomic Health (GHDX) Expected to Announce Quarterly Sales of $88.71 MillionGenomic Health (GHDX) Expected to Announce Quarterly Sales of $88.71 Million
www.americanbankingnews.com - April 14 at 5:00 AM
Genomic Health (GHDX) Rating Increased to Hold at ValuEngineGenomic Health (GHDX) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - April 12 at 10:18 PM
Zacks: Analysts Anticipate Genomic Health (GHDX) to Post $0.01 EPSZacks: Analysts Anticipate Genomic Health (GHDX) to Post $0.01 EPS
www.americanbankingnews.com - April 12 at 3:19 AM
Genomic Health (GHDX) Cut to "Hold" at BidaskClubGenomic Health (GHDX) Cut to "Hold" at BidaskClub
www.americanbankingnews.com - April 11 at 11:01 AM
Why Is Genomic Health (GHDX) Up 1.6% Since Its Last Earnings Report?Why Is Genomic Health (GHDX) Up 1.6% Since Its Last Earnings Report?
finance.yahoo.com - April 9 at 9:43 AM
Genomic Health (GHDX) Receives Consensus Recommendation of "Hold" from BrokeragesGenomic Health (GHDX) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - April 8 at 3:36 AM
Epic Sciences and Genomic Health announces favorable draft LCD on medicare coverage for use of Oncotype DX AR-V7 Nucleus Detect testEpic Sciences and Genomic Health announces favorable draft LCD on medicare coverage for use of Oncotype DX AR-V7 Nucleus Detect test
seekingalpha.com - April 2 at 9:57 AM
Genomic Health (GHDX) Upgraded to "Buy" at BidaskClubGenomic Health (GHDX) Upgraded to "Buy" at BidaskClub
www.americanbankingnews.com - March 30 at 1:06 PM
Epic Sciences and Genomic Health Announce Favorable Draft Local Coverage Determination (LCD) on Medicare Coverage for Use of the Oncotype DX® AR-V7 Nucleus Detect™ Test in Patients with Metastatic Castration-Resistant Prostate CancerEpic Sciences and Genomic Health Announce Favorable Draft Local Coverage Determination (LCD) on Medicare Coverage for Use of the Oncotype DX® AR-V7 Nucleus Detect™ Test in Patients with Metastatic Castration-Resistant Prostate Cancer
finance.yahoo.com - March 30 at 9:35 AM
Intrinsic Calculation For Genomic Health Inc (NASDAQ:GHDX) Shows Investors Are OverpayingIntrinsic Calculation For Genomic Health Inc (NASDAQ:GHDX) Shows Investors Are Overpaying
finance.yahoo.com - March 30 at 9:35 AM
Genomic Healths (GHDX) Buy Rating Reaffirmed at Canaccord GenuityGenomic Health's (GHDX) Buy Rating Reaffirmed at Canaccord Genuity
www.americanbankingnews.com - March 28 at 12:58 PM
$88.76 Million in Sales Expected for Genomic Health (GHDX) This Quarter$88.76 Million in Sales Expected for Genomic Health (GHDX) This Quarter
www.americanbankingnews.com - March 28 at 10:19 AM

SEC Filings

Genomic Health (NASDAQ:GHDX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Genomic Health (NASDAQ:GHDX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Genomic Health (NASDAQ GHDX) Stock Chart for Saturday, May, 26, 2018

Loading chart…

This page was last updated on 5/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.